| pubmed-article:8287873 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8287873 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8287873 | lifeskim:mentions | umls-concept:C0154143 | lld:lifeskim |
| pubmed-article:8287873 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:8287873 | lifeskim:mentions | umls-concept:C0086960 | lld:lifeskim |
| pubmed-article:8287873 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:8287873 | lifeskim:mentions | umls-concept:C1554217 | lld:lifeskim |
| pubmed-article:8287873 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:8287873 | pubmed:dateCreated | 1994-2-22 | lld:pubmed |
| pubmed-article:8287873 | pubmed:abstractText | The long-term effects of two schedules of radioiodine therapy in patients with toxic multinodular goitre were evaluated. Forty-five patients (group A) were treated with low doses and 58 patients (group B) with calculated doses adjusted for thyroid weight (1.85-3.70 MBq/g) and radioactive iodine uptake. Follow-up (mean +/- SEM) was 4.3 +/- 0.2 years and 5.2 +/- 0.3 years, respectively (P > 0.1). At the end of follow-up, hyperthyroidism was successfully reversed in 73% (group A) and 88% (group B). In each group, hypothyroidism was present in 7%. The total dose per gram of thyroid tissue was not significantly different in groups A and B (2.1 +/- 0.2 vs 2.7 +/- 0.2 MBq/g). However, for patients treated with calculated doses the number of 131I administrations was significantly lower (1.3 +/- 0.1) than for patients treated with low doses (2.2 +/- 0.2), and the percentage of patients who were adequately treated with a single dose was more than twice as high (66% in group B versus 27% in group A). Euthyroidism was reached within a significantly shorter time after treatment with calculated doses (median time 0.6 years in group B vs 1.5 years in group A; life table analysis). It is concluded that radioiodine is an effective treatment for toxic multinodular goitre with a low risk of post-treatment hypothyroidism and that calculated (higher) doses appear to be preferable to low doses. | lld:pubmed |
| pubmed-article:8287873 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8287873 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8287873 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8287873 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8287873 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8287873 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:8287873 | pubmed:issn | 0340-6997 | lld:pubmed |
| pubmed-article:8287873 | pubmed:author | pubmed-author:KloppenborgP... | lld:pubmed |
| pubmed-article:8287873 | pubmed:author | pubmed-author:HermusA RAR | lld:pubmed |
| pubmed-article:8287873 | pubmed:author | pubmed-author:CorstensF HFH | lld:pubmed |
| pubmed-article:8287873 | pubmed:author | pubmed-author:HuysmansD ADA | lld:pubmed |
| pubmed-article:8287873 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8287873 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:8287873 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8287873 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8287873 | pubmed:pagination | 1056-62 | lld:pubmed |
| pubmed-article:8287873 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:8287873 | pubmed:meshHeading | pubmed-meshheading:8287873-... | lld:pubmed |
| pubmed-article:8287873 | pubmed:meshHeading | pubmed-meshheading:8287873-... | lld:pubmed |
| pubmed-article:8287873 | pubmed:meshHeading | pubmed-meshheading:8287873-... | lld:pubmed |
| pubmed-article:8287873 | pubmed:meshHeading | pubmed-meshheading:8287873-... | lld:pubmed |
| pubmed-article:8287873 | pubmed:meshHeading | pubmed-meshheading:8287873-... | lld:pubmed |
| pubmed-article:8287873 | pubmed:meshHeading | pubmed-meshheading:8287873-... | lld:pubmed |
| pubmed-article:8287873 | pubmed:meshHeading | pubmed-meshheading:8287873-... | lld:pubmed |
| pubmed-article:8287873 | pubmed:meshHeading | pubmed-meshheading:8287873-... | lld:pubmed |
| pubmed-article:8287873 | pubmed:meshHeading | pubmed-meshheading:8287873-... | lld:pubmed |
| pubmed-article:8287873 | pubmed:meshHeading | pubmed-meshheading:8287873-... | lld:pubmed |
| pubmed-article:8287873 | pubmed:meshHeading | pubmed-meshheading:8287873-... | lld:pubmed |
| pubmed-article:8287873 | pubmed:meshHeading | pubmed-meshheading:8287873-... | lld:pubmed |
| pubmed-article:8287873 | pubmed:meshHeading | pubmed-meshheading:8287873-... | lld:pubmed |
| pubmed-article:8287873 | pubmed:meshHeading | pubmed-meshheading:8287873-... | lld:pubmed |
| pubmed-article:8287873 | pubmed:meshHeading | pubmed-meshheading:8287873-... | lld:pubmed |
| pubmed-article:8287873 | pubmed:meshHeading | pubmed-meshheading:8287873-... | lld:pubmed |
| pubmed-article:8287873 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8287873 | pubmed:articleTitle | Long-term results of two schedules of radioiodine treatment for toxic multinodular goitre. | lld:pubmed |
| pubmed-article:8287873 | pubmed:affiliation | Department of Nuclear Medicine, University Hospital Nijmegen St. Radboud, The Netherlands. | lld:pubmed |
| pubmed-article:8287873 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8287873 | lld:pubmed |
